Status:
NOT_YET_RECRUITING
Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis.
Lead Sponsor:
University Hospital, Angers
Collaborating Sponsors:
University Hospital, Brest
Nantes University Hospital
Conditions:
Myeloproliferative Neoplasm
Eligibility:
All Genders
18+ years
Brief Summary
First-line treatment for patients with polycythemia vera, essential thrombocythemia, and pre-myelofibrosis is based on hydroxyurea or pegylated interferon. The objective of treatment is to prevent thr...
Eligibility Criteria
Inclusion
- Adults with polycythemia vera, essential thrombocythemia, or pre-myelofibrosis.
- Indication for first-line treatment with hydroxyurea or pegylated interferon.
- Consent to participate.
- Affiliated to social security.
Exclusion
- Previous treatment.
- Other on-going malignancy, including overt myelofibrosis.
- Other treatment such as phlebotomy solely, ruxolitinib, anagrelide, or pipobroman.
Key Trial Info
Start Date :
September 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 4 2029
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05440838
Start Date
September 8 2022
End Date
October 4 2029
Last Update
July 1 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.